How effective is Apelvis in treating breast cancer? Applicable population and clinical research data analysis

Alpelisib (Alpelisib) is an oral PI3Kα (phosphatidylinositol3-kinase α) inhibitor, mainly used for treatment pan>HRpositive, HER2negative, and PIK3CAmutated advanced or metastatic breast cancer. Its mechanism of action is to reduce the proliferation and survival of tumor cells by inhibiting the PI3K signaling pathway, thereby delaying disease progression. Apelvis is often used in combination with endocrine therapy (such as fulvestrant) to overcome endocrine resistance and improve treatment efficacy.

In terms of the applicable population, Apelvis is mainly used for patients with advanced breast cancer who are HR positive, HER2 negative, and PIK3CA mutated. It is especially suitable for patients who have received endocrine therapy in the past but whose disease still progresses. PIK3CAGene mutations can lead to abnormal activation of the PI3K/AKT/mTOR pathway, making tumor cells resistant to traditional endocrine therapy, and the specific inhibitory effect of Apelvis can effectively improve the treatment prognosis of such patients. Therefore, before using apelvis, it is usually necessary to confirm whether the patient carries the PIK3CA mutation through genetic testing.

Clinical study data show that the SOLAR-1 study is a pivotal III phase clinical trial evaluating the combination of apelvis and fulvestrant. The efficacy of HR positive, HER2 negative, PIK3CA mutated breast cancer. The results showed that compared with fulvestrant alone, the progression-free survival (PFS) of the apelvis combination treatment group was significantly longer, from 5.7 pan> months to 11.0 months, the risk of disease progression or death was reduced by 35%. In addition, the study also showed that apelvis resulted in a higher objective response rate (ORR) in patients with PIK3CA mutations (35.7% vs. 16.2%), further supporting its efficacy in this specific population.

In summary, Apelvis has shown good efficacy in HR positive, HER2 negative, and PIK3CA mutated breast cancer patients, and can significantly delay disease progression and improve treatment response rate. However, this drug may cause adverse reactions such as hyperglycemia, rash, diarrhea, etc. Therefore, blood sugar levels and skin reactions need to be closely monitored during use, and corresponding management measures must be taken. For patients who meet the indications, Apelvis provides an effective treatment option to overcome endocrine resistance and further optimizes the personalized treatment strategy for breast cancer.

Reference materials:https://www.piqray.com/